FRANKFURT, Feb 24 (Reuters) - U.S. health regulators have issued a warning letter to German healthcare conglomerate Fresenius SE in connection with generic products made at unit APP Pharmaceuticals '...
Jan 23 (Reuters) - Medicines Co said it settled a patent lawsuit with generic drug maker APP Pharmaceuticals , a unit of German healthcare group Fresenius SE , over a copycat version of Medicines'...
… the early expiration of Angiomax over a filing error several years ago . The patent challenges from Teva TEVA and APP Pharmaceuticals continue to play out , and Medicines indicated it was fighting these efforts vigorously . While there are a lot …
… snafu. While Medicines obtained two new patents for the product during the year, generic firms Teva TEVA and APP Pharmaceuticals have filed challenges to these patents, and Medicines has countered with lawsuits against both firms. We have …
… Fresenius SE ( FRE3 : GY ) announced that it was buying APP Pharmaceuticals ( APPX ) for $ 4 . 6 billion , or around $ 23 a share . The ..... looked unusual , given that normal open interest for APPX options had been “ very light ” . But on Thursday …
We're dropping coverage of APP Pharmaceuticals APPX in order to focus on other investment opportunities in the health-care sector. Following the recent spin-off of Abraxis BioScience …